A new study by the American Society of Clinical Oncology (ASCO) is now available, which chronicles the current realities of the cancer care system and examines trends in the oncology workforce.
A new study by the American Society of Clinical Oncology (ASCO) is now available, which chronicles the current realities of the cancer care system and examines trends in the oncology workforce and practice environment that are affecting patient care and access. The report is titled "The State of Cancer Care in America: 2015."
According to the ASCO report, there is a wider array of treatment options than ever before for many cancers. In 2014, the FDA added 10 new treatments to its list of more than 170 approved anti-cancer agents, and also approved four new medical devices and tests that may improve patient outcomes through early detection of cancer. In addition, more than 770 cancer therapies are in the research and development pipeline and therapies are demonstrating dramatic improvements in efficacy.
However, the report noted growing challenges to high-quality care delivery, some are as follows:
· Due largely to an aging population, a dramatic 45% increase in cancer incidence is expected by 2030, leading to an overwhelming demand for cancer care and post-treatment services in the relatively near future.
· Benefits of cancer screening and treatment advances have not been experienced consistently across racial and ethnic groups, as evidenced by differences in incidence and mortality rates. African Americans, for example, are 2.5 percent more likely to develop cancer than whites and 19.6 percent more likely to die from cancer.
· Nation's ability to care for an increasing number of people with cancer depends on a workforce that is sufficient in size, diversity, and geographic reach.
· Continuation of practice consolidations, as one quarter of all community-based oncology practices report the likelihood of becoming affiliated with a hospital over the next year.
· Industry needs to find better ways to pay for and incentivize high-quality, value-based care. ASCO is currently developing and testing an alternative payment approach that reflects the current realities of oncology practices and ensures that patients receive the full range of services that are integral to their care.
ASCO made a number of recommendations directed to Congress, one of which calls on increasing the budgets of the National Institutes of Health and the National Cancer Institute by at least $32 billion and $5.32 billion, respectively. It also states: "As the 21st Century Cures initiative moves forward in the House -- and the "Innovation for Healthier Americans" legislation in the Senate -- ensure interoperability of medical records and provide the resources to enable practices to track and report quality measures, while serving patients in an environment of widespread change in care delivery and payment systems."
Read the full release here.
Investigational Pain Therapy Cebranopadol Succeeds in Second Phase III Clinical Trial
March 6th 2025Tris Pharma’s first-in-class oral dual-NMR agonist achieved its primary endpoint in the ALLEVIATE-2 study by demonstrating a statistically significant and high level of pain reduction compared to placebo.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Xolair Outperforms Oral Immunotherapy in Landmark Phase III OUtMATCH Food Allergy Trial
March 3rd 2025Xolair (omalizumab) shows superior efficacy and safety compared to multi-allergen oral immunotherapy in treating food allergies in the Phase III OUtMATCH trial, suggesting the potential to facilitate the introduction of allergenic foods into patients' diets after treatment.